AKBA trades 7.2% below Wall Street's consensus target of $1.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AKBA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 12 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Akebia Therapeutics, Inc. (AKBA) has a Wall Street consensus price target of $1.00, based on estimates from 12 covering analysts. With the stock currently trading at $0.93, this represents a potential upside of +7.2%. The company has a market capitalization of $250M.
Analyst price targets range from a low of $1.00 to a high of $1.00, representing a 0% spread in expectations. The median target of $1.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, AKBA trades at a trailing P/E of -44.8x. Analysts expect EPS to grow -27.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.86 | +2.6% | Buy | 40.6x | 24 |
 PTGXProtagonist Therapeutics, Inc. | $8.9B | $138.70 | $176.29 | +27.1% | Buy | 29.7x | 26 |
 CYCNCyclerion Therapeutics, Inc. | $16M | $23.52 | — | — | — | — | — |
 ANIPANI Pharmaceuticals, Inc. | $1.7B | $74.43 | $104.33 | +40.2% | Buy | 8.0x | 10 |
 HALOHalozyme Therapeutics, Inc. | $13.3B | $112.44 | $103.00 | -8.4% | Buy | 13.4x | 27 |
 PRTAProthena Corporation plc | $454M | $8.68 | $30.00 | +245.6% | Buy | 78.9x | 28 |
 FXNCFirst National Corporation | $266M | $29.40 | $21.00 | -28.6% | Buy | 12.1x | 1 |
 GSKGSK plc | $99.6B | $49.71 | $60.00 | +20.7% | Hold | 13.8x | 29 |
 AMGNAmgen Inc. | $219.2B | $406.09 | $393.72 | -3.0% | Buy | 17.6x | 41 |
 RPRXRoyalty Pharma plc | $25.6B | $57.65 | $62.67 | +8.7% | Buy | 10.8x | 11 |
Quick answers to the most common questions about buying AKBA stock.
The consensus price target for AKBA is $1, close to the current price of $0.9326 (7.2% implied move). Based on 12 analyst estimates, the stock appears fairly valued near current levels.
AKBA has a consensus rating of "Buy" based on 12 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $1 implies 7.2% upside from current levels.
AKBA's current price is $0.9326 with a consensus target of $1 (7.2% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $1 for AKBA, while the most conservative target is $1. The consensus of $1 represents the median expectation. These targets typically reflect 12-month expectations.
AKBA is moderately covered, with 12 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AKBA stock forecast based on 12 Wall Street analysts shows a consensus price target of $1, with estimates ranging from $1 (bear case) to $1 (bull case). The median consensus rating is "Buy".
AKBA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $1 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AKBA analyst price targets range from $1 to $1, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.